Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a health diagnostics company headquartered in Salt Lake City, Utah, focused on precision pregnancy care and the early prediction of spontaneous preterm birth. News about Sera often centers on its PreTRM® Test, a blood-based biomarker test that provides individualized risk prediction for preterm birth in asymptomatic singleton pregnancies, and on the growing clinical and payer interest in this approach.
On this page, readers can find updates on Sera’s clinical research, including results and publications from the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study. Company press releases describe how the PRIME randomized controlled trial evaluated the PreTRM Test combined with targeted interventions and reported reductions in very early preterm births, NICU admissions, neonatal complications, and NICU length of stay compared with standard care.
SERA news coverage also includes quarterly financial results, payer and Medicaid pilot initiatives, and commentary on commercial progress for the PreTRM Test. The company has highlighted engagement with Medicaid plans and other organizations in multiple states, as well as presentations at medical and investor conferences where leadership discusses clinical data, health economic analyses, and market adoption efforts.
Investors and healthcare professionals following SERA can use this news feed to review announcements related to leadership appointments, conference presentations, regulatory filings summarized in press releases, and ongoing work to position pregnancy biomarker testing within prenatal care. Bookmark this page to access a consolidated view of Sera Prognostics’ latest press releases, study milestones, and business updates connected to its focus on improving outcomes for mothers and newborns.
Sera Prognostics, Inc. (Nasdaq: SERA) has been added to the Russell 2000 Index effective September 20, 2021, enhancing its visibility within the investment community. This milestone follows the company’s transition to a public entity in July 2021. The company focuses on improving maternal and neonatal health through innovative biomarker testing, particularly its PreTRM test, which predicts preterm birth risk. Sera aims to expand revenue and shareholder value through increased awareness and adoption of its services.
Sera Prognostics, focused on maternal and neonatal health, announced Dr. Michael R. Foley as Chief Medical Officer starting January 2022. He brings over 20 years of Maternal-Fetal Medicine experience and has chaired Obstetrics and Gynecology at the University of Arizona. Dr. Foley will lead medical activities and help expand access to Sera's PreTRM® risk information, aimed at improving pregnancy outcomes. His appointment aligns with Sera's mission to provide innovative diagnostic solutions for better individualized prenatal care.
Sera Prognostics published a study demonstrating the clinical benefits of its PreTRM® testing, revealing a 20% reduction in preterm births and significant cost savings. The analysis of over 40,000 health plan members indicated a net savings of $863 per pregnant woman, totaling a possible $54 million reduction in costs. Furthermore, the study could forecast annual savings of over $850 million for U.S. health plans with full adoption of the test-and-treat strategy. The results enhance Sera's strategy for improving pregnancy outcomes while reducing healthcare expenses.
Sera Prognostics Inc. (Nasdaq: SERA), dedicated to maternal and neonatal health, will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 21, 2021, at 8:15 a.m. ET. CEO Gregory C. Critchfield will discuss the company’s achievements and updates. Investors can join one-on-one meetings post-presentation. Sera’s PreTRM® test is a vital tool for predicting preterm birth risks, vital for personalized clinical decisions. The webcast will be available for 90 days on Sera's website.
Sera Prognostics Inc. (SERA) reported financial results for Q2 2021, showing revenue of $20,000, a significant increase from $6,000 in Q2 2020. Despite this growth, the company incurred a net loss of $6.3 million, up from $4.7 million year-over-year. Operating expenses rose to $7.4 million, driven by increased R&D and SG&A costs. A key highlight includes a strategic partnership with Anthem to provide their PreTRM® test to eligible pregnant members. The company had $90.9 million in cash as of June 30, 2021, following a $75 million IPO in July 2021, aimed at supporting commercialization and clinical studies.
Sera Prognostics has reported significant findings from the PREVENT-PTB study published in the American Journal of Perinatology. This study, evaluating the impact of the PreTRM® test on neonatal care, indicates that NICU and total hospital stays for preterm infants were reduced by over 70%. The results showed a 66% reduction in severe morbidity and newborn death rates. Sera's PreTRM® test demonstrated efficacy in managing pregnancies at higher risk for preterm births, although the trial was terminated early due to limited resources. These findings could enhance neonatal healthcare and reduce associated costs.
Sera Prognostics Inc., known as The Pregnancy Company®, has priced its initial public offering at $16.00 per share, offering 4,687,500 shares and expecting gross proceeds of approximately $75.0 million. Shares will begin trading on the Nasdaq under the symbol 'SERA' starting July 15, 2021, with the offering set to close on July 19, 2021, pending customary conditions. The company focuses on enhancing maternal and neonatal health through innovative pregnancy biomarkers, and has a pipeline dedicated to predicting preterm birth risks.